Stereotactic body radiation therapy for prostate cancer. (September 2011)

• Record Type: Journal Article
• Authors: Ishiyama, Hiromichi; Teh, Bin S; Lo, Simon S; Mathews, Thomas; Blanco, Angel; Amato, Robert; Ellis, Rodney J; Mayr, Nina A; Paulino, Arnold C; Xu, Bo; Butler, Brian E
• Is Part Of: Future oncology. Volume 7:Number 9(2011)
• Page Start: 1077
• Page End: 1086
• Publication Date: 2011-09
• Subjects: outcome -- prostate cancer -- stereotactic body radiation therapy -- toxicity; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.11.86
• Languages: English
• ISSNs: 1479-6694

Abstract

Stereotactic body radiation therapy (SBRT) is a promising treatment option for prostate cancer. Hypofractionation regimens, such as SBRT, may be more advantageous compared with conventional regimens because low αα:ββ ratio of prostate cancer has high sensitivity to dose per fraction. In addition, a smaller and tighter margin with SBRT is expected to provide a low toxicity rate without reducing tumor control. The purpose of this article is to examine radiobiological, technical and clinical aspects of SBRT for prostate cancer.